Go to deals
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Geoff  Nash

Geoff Nash

Partner
London, United Kingdom
Oaklins Cavendish

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination
Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more
Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes
Private Equity | Healthcare

Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes

Groupe Serenis and three other independent clinics have acquired Clinique du Chateau de Vernhes from the funding family.

Learn more
Biosynex has acquired Para’kito
Healthcare

Biosynex has acquired Para’kito

Biosynex has acquired Para’kito, operated by Hong-Kong based Evergreen Land Ltd. The transaction includes assets and IP and the exclusive right to commercialize the brand in Europe, Africa and South America.

Learn more